Central Nervous System

PV QA 2 - Poster Viewing Q&A 2

MO_1_2486 - Initial Findings of Analysis of Circulating Tumor Cells in Patients with Brain Metastases of Breast Cancer

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Initial Findings of Analysis of Circulating Tumor Cells in Patients with Brain Metastases of Breast Cancer
D. G. Castro1, C. Pellizzon2, G. R. M. Gondim1, M. L. G. Silva3, M. J. Chen1, R. C. Fogaroli1, H. Ramos1, T. M. Coelho4, A. C. Scintini5, A. C. Braun5, C. R. Luiz5, E. A. Abdallah5, L. S. Yu5, V. F. Calsavara5, and L. T. D. Chinen5; 1A C Camargo Cancer Center, Sao Paulo, Brazil, 2AC Camargo Cancer Center, Sao Paulo, Brazil, 3AC Camargo Cancer Center, sao paulo, Brazil, 4A.C.Camargo Cancer Center, Sao Paulo, Brazil, 5AC Camargo Cancer Center, São Paulo, Brazil

Purpose/Objective(s): Predicting the risk of early distant brain failure is a useful and demanding resource for management decisions in patients candidates to local treatment of brain metastasis. This developing study aims to analyse the correlation between circulating tumor cells (CTC) and brain disease control after stereotactic radiotherapy/radiosurgery (SRT) for brain metastasis of breast cancer (BMBC). In this report, we describe initial findings of qualitative and quantitative analysis of CTC of patients with BMBC.

Materials/Methods: Prospective assessment of the number of CTC before (CTC1) and 4-5 weeks after (CTC2) SRT for BMBC. In this analysis, partial results of the first 20 enrolled patients for the study between November 2016 and May 2017 are reported. Number of CTC and its protein expressions, as HER-2, EGFR, Notch1, COX2 and ST6GALNAC5 at both moments are characterized.

Results: The median age at SRT was 49 years. Immunophenotype was HER2-positive in 55%, luminal B in 25% and triple negative in 20% of patients and the diagnosis-specific graded prognostic assessment (DS-GPA) was 1.5-2 in 20% and 2.5-4 in 80% of them. CTC were detected in all 20 patients before SRT and the median CTC1 was 1.63 CTC/mL. After SRT, CTC was detected in 17 of 18 patients (2 deaths between CTC1 and CTC2) and the median CTC2 was 1.13 CTC/mL. After a median follow-up of 8.2 months, there were 6 patients with distant brain failure and 6 deaths. The expression of HER-2, EGFR, Notch1, COX2 and ST6GALNAC5 was 5%, 0%, 40%, 85% and 35% at CTC1 and 6%, 29%, 47%, 76% and 53% at CTC2, respectively.

Conclusion: CTC are detectable in almost all patients with BMBC. The expression of Notch1, COX2 and ST6GALNAC5T are present in a significant number of patients at both moments, which may allow a molecular characteriziation of breast cancer CTC associated with brain metastasis. These initial findings suggest that CTC is a potential biomarker of early brain disease control in patients candidates to SRT (NCT02941536).

Author Disclosure: D.G. Castro: None. C. Pellizzon: None. M.G. Silva: None. M.J. Chen: None. R.C. Fogaroli: None. H. Ramos: None. V.F. Calsavara: None.

Send Email for Douglas Castro


Assets

MO_1_2486 - Initial Findings of Analysis of Circulating Tumor Cells in Patients with Brain Metastases of Breast Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Initial Findings of Analysis of Circulating Tumor Cells in Patients with Brain Metastases of Breast Cancer